Industry News
Pharmaceutical Industry News
The agency identified 14 cases of…
The agency identified 14 cases of vitamin B6 deficiency-associated seizures in patients using the common Parkinson's disease drug combo of levodopa and carbidopa.
Watch out, Johnson & Johnson….
Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure on the pharma giant’s injectable Rybrevant in non-small cell lung cancer.
Novartis is investing more than…
Novartis is investing more than 3.3 billion Chinese yuan (roughly $480 million) to soup up its manufacturing facility in Beijing and strengthen its R&D campus in Shanghai, where the company’s China headquarters are also located.
The FDA has scheduled a public…
The FDA has scheduled a public hearing for June 12 to hear input on the Commissioner’s National Priority Voucher program, which it introduced last June. So far, the program has resulted in four ultraspeedy drug
Seventeen large pharmaceutical…
Seventeen large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.
With patents expiring today in…
With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions in the country, with
Not long after lending its support…
Not long after lending its support to a documentary aimed at shining a light on the often-overlooked stories of women with hemophilia, Sanofi is continuing its film-focused collaboration with patient engagement agency Believe Limited.
The status of the CDC’s vaccine…
The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the ACIP—whose appointment was invalidated by a federal judge Monday—declared that the group was being
The new FDA nod makes Rhythm…
The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired hypothalamic obesity and brings the drug's first expansion beyond rare genetic-driven obesities.
The company is working with…
The company is working with regulators to ensure stable ongoing supply for the one-time gene therapy, it said in a community letter.
China approved the world’s first…
China approved the world's first commercial brain-computer interface. AstraZeneca is building new cell therapy centers in Shanghai. Astellas ended a T-cell engager pact with CytomX Therapeutics. And more.
Still basking in the afterglow of…
Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly pressured
PrescriberPoint helps clinicians…
PrescriberPoint helps clinicians reduce administrative burden and ensure patient access to therapy across the modern prescribing journey.
Collegium Pharmaceutical will pay…
Collegium Pharmaceutical will pay $650 million upfront to acquire ADHD drug Azstarys from Corium Therapeutics. The deal, which includes an additional $135 million in potential milestone payments, gives Collegium a second branded ADHD treatment, Azstarys, along
A new bill introduced in the…
A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to their otherwise unbranded disease awareness initiatives.
Lynavoy is now the first…
Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary cholangitis.
As part of its $15 billion…
As part of its $15 billion investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to the modality in Shanghai.
The New Alzheimer’s Blood Tests: What to Know
The tests could help to improve dementia care, but scientists say there are still some caveats and unknowns.
Axplora, a German CDMO that…
Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug conjugates, will shell out $60 million to expand its Farmabios manufacturing facility in Gropello Cairoli, Italy.
After an FDA snub in a broader…
After an FDA snub in a broader metastatic castration-resistant prostate cancer population, Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 readout in metastatic hormone-sensitive prostate cancer.